Johnson & Johnson (NYSE:JNJ) Given New $185.00 Price Target at TD Securities

Johnson & Johnson (NYSE:JNJ) had its target price reduced by TD Securities from $195.00 to $185.00 in a research report released on Thursday morning, BayStreet.CA reports.

A number of other analysts have also issued reports on the stock. Cantor Fitzgerald restated an overweight rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Monday, July 1st. Morgan Stanley lifted their price objective on Johnson & Johnson from $167.00 to $169.00 and gave the company an equal weight rating in a research report on Thursday. The Goldman Sachs Group started coverage on Johnson & Johnson in a research report on Thursday, May 30th. They set a neutral rating and a $160.00 target price on the stock. HSBC upgraded Johnson & Johnson from a hold rating to a buy rating and lifted their price target for the company from $169.00 to $170.00 in a report on Thursday, April 18th. Finally, Bank of America decreased their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a neutral rating on the stock in a research report on Wednesday, April 17th. Eight investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of Moderate Buy and a consensus price target of $175.00.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $154.69 on Thursday. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.97. The company has a market capitalization of $372.29 billion, a price-to-earnings ratio of 9.64, a PEG ratio of 2.70 and a beta of 0.52. The stock has a fifty day moving average of $148.36 and a two-hundred day moving average of $153.34. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.79%. The firm had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. During the same quarter in the previous year, the company posted $2.80 EPS. The firm’s revenue for the quarter was up 4.3% on a year-over-year basis. On average, analysts anticipate that Johnson & Johnson will post 10.07 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a yield of 3.21%. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Christopher J. Hasenberg Inc acquired a new position in Johnson & Johnson during the 1st quarter worth approximately $31,000. Keener Financial Planning LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $40,000. WFA Asset Management Corp boosted its stake in shares of Johnson & Johnson by 61.4% in the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after purchasing an additional 97 shares during the period. Vermillion & White Wealth Management Group LLC acquired a new stake in Johnson & Johnson during the 4th quarter valued at $44,000. Finally, Disciplined Equity Management Inc. purchased a new stake in Johnson & Johnson during the 4th quarter worth $45,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.